Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -2,12 +2,8 @@
2	2	{{toc/}}
3	3	{{/box}}
4	4
5		-= Paragraph 1 =
	5	+= Overview =
6	6
7		-Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
8		-
9		-==== Overview ====
10		-
11	11	Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development.
12	12
13	13	Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 million and $6.4 million for the three and six months ended June 30, 2018, respectfully and $3.8 million and $8.5 million for the three and six months ended June 30, 2017, respectfully. The company anticipate that a portion of its operating expenses will continue to be related to research and development as the company continue to develop Twirla. Substantially all of its resources are currently dedicated to developing and seeking regulatory approval for Twirla. The company believe that its cash and cash equivalents as of June 30, 2018, will be sufficient to meet its operating requirements into the second quarter of 2019. The company will require additional capital to fund its operating needs for the remainder of the second quarter of 2019 and beyond, including, among other items, the resumption and completion of its commercialization plan for Twirla, which primarily includes the validation of its manufacturing process and the commercial launch of Twirla, if approved, and advancing the development of its other potential product candidates.